These 3 Dividend Stocks Yield Less Than 10-Year Treasuries Over 5%. Here's Why They Are Better Buys Anyway.

Impact · against what's priced in

The article provides no new catalysts for ABT or CVS, as the reported Q2 beats and raised guidance were already fully absorbed into the reconstructions. The mentioned analyst target upside for CVS is specifically noted in the reconstruction as something the market currently declines to pay for.

ABT+0.00: Already priced in
The price assumes: The Q2 2026 earnings beat and the raised full-year profit guidance

These 3 Dividend Stocks Yield Less Than 10-Year Treasuries Over 5%. Here's Why They Are Better Buys Anyway.

What matters in this story

Re:Vision Founder Dr Trevor Gray Shifts Focus to Second Opinions and Clinical Mentoring

These 3 Dividend Stocks Yield Less Than 10-Year Treasuries Over 5%. Here's Why They Are Better Buys Anyway.

What matters in this story

Re:Vision Founder Dr Trevor Gray Shifts Focus to Second Opinions and Clinical Mentoring

How each ticker is affected

Track these names every morning.

HIMS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMS

UnitedHealth: Q3 Confirms The Bull Case

Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMS

Beta Bionics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Beta Bionics, Inc. - BBNX

These 3 Dividend Stocks Yield Less Than 10-Year Treasuries Over 5%. Here's Why They Are Better Buys Anyway.

What matters in this story

Next reads from the same story arc

Re:Vision Founder Dr Trevor Gray Shifts Focus to Second Opinions and Clinical Mentoring

These 3 Dividend Stocks Yield Less Than 10-Year Treasuries Over 5%. Here's Why They Are Better Buys Anyway.

What matters in this story

Next reads from the same story arc

Re:Vision Founder Dr Trevor Gray Shifts Focus to Second Opinions and Clinical Mentoring

How each ticker is affected

Track these names every morning.

HIMS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMS

UnitedHealth: Q3 Confirms The Bull Case

Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMS

Beta Bionics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Beta Bionics, Inc. - BBNX